Article
Immunology
William T. Connell, Julie Hong, Wilson Liao
Summary: Genetic factors, including rs35569429 and HLA-C*06:02, are associated with the response to ustekinumab therapy in psoriasis. The presence of the deletion allele of rs35569429 and being HLA-C*06:02 negative are associated with a lower treatment response rate.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Dermatology
Merav Koschitzky, Kristina Navrazhina, Michael S. Garshick, Juana Gonzalez, Joseph Han, Sandra Garcet, James G. Krueger
Summary: This study aimed to identify biomarkers of cardiovascular (CV) risk in psoriasis blood that are reduced by ustekinumab. The results showed that 43 out of 276 proteins were down-regulated after treatment, and 8 of them were initially elevated above thresholds associated with enhanced CV risk.
EXPERIMENTAL DERMATOLOGY
(2022)
Article
Medicine, General & Internal
Laida Elberdin, Rosa M. Fernandez-Torres, Maria Mateos, Maria Outeda, Eva Blanco, Maria I. Gomez-Besteiro, Isabel Martin-Herranz, Eduardo Fonseca
Summary: This study found a positive correlation between ustekinumab concentration and clinical response in psoriatic patients, suggesting ustekinumab concentration could be used to predict treatment efficacy. The presence of anti-ustekinumab antibodies may serve as a potential cause for treatment failure.
FRONTIERS IN MEDICINE
(2022)
Review
Medicine, General & Internal
Luyang Kong, Dawei Huang, Jiajing Lu, Yuexin Zhang, Ying Li, Xuemei Yi, Yuling Shi
Summary: Ustekinumab, a biological therapy for psoriasis, has been associated with adverse events such as injection site reactions, nasopharyngitis, headaches, infections, and bullous pemphigoid (BP). This case report describes a male patient who developed BP twice after ustekinumab treatment for psoriasis. Discontinuation of ustekinumab and administration of methotrexate, minocycline, and topical corticosteroids successfully controlled both the patient's psoriasis and BP. Considering the increasing use of biologics in psoriasis patients, BP should be recognized as a potential adverse event of ustekinumab.
FRONTIERS IN MEDICINE
(2023)
Review
Medicine, General & Internal
Maria-Angeles Ferrer-Alcala, Manuel Sanchez-Diaz, Salvador Arias-Santiago, Alejandro Molina-Leyva
Summary: Psoriasis and hidradenitis suppurativa have an impact on pregnancy and fertility, including decreased fertility and unpredictable disease evolution during pregnancy. Treatment during pregnancy may change, but biologic therapies do not appear to increase the risk of adverse events.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Dermatology
Ricardo Ruiz-Villaverde, Fiorella Vasquez Chinchay, Lourdes Rodriguez-Fernandez-Freire, Jose C. Armario-Hita, Amalia Perez-Gil, Manuel Galan-Gutierrez
Summary: This retrospective observational study examined the outcomes of psoriatic patients with moderate-to-severe psoriasis who switched from ustekinumab to guselkumab treatment. The results showed that guselkumab administered every 12 weeks without induction achieved good effectiveness and safety profiles in clinical practice.
DERMATOLOGIC THERAPY
(2022)
Article
Immunology
Yu-Huei Huang, Meng-Jiun Chiou, Shun-Fa Yang, Chang-Fu Kuo
Summary: This study investigates the association between paternal psoriasis and adverse neonatal outcomes. The results show that newborns of fathers with psoriasis have significantly higher risk of developing psoriasis, atopic dermatitis, and allergic rhinitis. On the other hand, newborns of mothers with psoriasis have increased risk of low birth weight, low Apgar scores, and psoriasis.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Dermatology
R. B. Warren, J. B. Hansen, K. Reich, C. Paul, L. Puig
Summary: Modern biologics can achieve complete skin clearance in 30-45% of psoriasis patients. This study compared the effectiveness of brodalumab and ustekinumab in achieving PASI 90 and 100 responses, finding that brodalumab resulted in significantly higher levels of skin clearance, longer sustained response, and greater cumulative treatment benefit compared to ustekinumab. Additionally, there was a significant positive association between PASI response level and health-related quality of life.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Dermatology
Elzbieta Halina Klujszo, Dorota Zarebska-Michaluk, Beata Krecisz, Anna Witkowska
Summary: Biological therapies used in psoriasis treatment such as Ustekinumab (UST) pose a risk of reactivating hepatitis B virus (HBV) infection. However, observations suggest that UST therapy is a safe option for patients with resolved HBV infection, as there were no signs of HBV reactivation in the studied patients.
DERMATOLOGIC THERAPY
(2022)
Article
Gastroenterology & Hepatology
Katarina Mitrova, Barbora Pipek, Martin Bortlik, Ludek Bouchner, Jan Brezina, Tomas Douda, Tomas Drasar, Pavel Klvana, Pavel Kohout, Vaclav Leksa, Petra Minarikova, Ales Novotny, Pavel Svoboda, Jan Skorpik, Jan Ulbrych, Marek Veinfurt, Blanka Zborilova, Milan Lukas, Dana Duricova
Summary: The safety of ustekinumab and vedolizumab treatment during pregnancy was evaluated in this study. The outcomes of pregnancy and postnatal infants were found to be favorable. Ustekinumab had a similar infant-to-maternal drug level ratio, while vedolizumab had an inverse ratio compared to anti-TNF preparations.
JOURNAL OF CROHNS & COLITIS
(2022)
Review
Gastroenterology & Hepatology
Uma Mahadevan, Saule Naureckas, Ilia Tikhonov, Yiting Wang, Connie B. Lin, Anja Geldhof, C. Janneke van der Woude
Summary: This study evaluated the pregnancy outcomes of patients exposed to ustekinumab during pregnancy. The results showed that the rates of adverse pregnancy outcomes or congenital anomalies with ustekinumab exposure were similar to those reported for the general population in the US, indicating no increased risk associated with maternal or paternal exposure to ustekinumab.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Rheumatology
William Tillett, Alexis Ogdie, Alun Passey, Patricia Gorecki
Summary: This study aimed to assess baseline differences between plaque psoriasis alone and concomitant PsA patients and to investigate the impact of these characteristics on ustekinumab (UST) persistence and outcomes. Results showed that patients with concomitant PsA had a greater comorbidity burden, including hypertension, diabetes, obesity, and depression, and a greater inability to work. PsA, female sex, and depression were associated with shorter UST persistence. These findings emphasize the need for patient-centric, multidisciplinary care in screening for and managing comorbidities in psoriasis and PsA treatment.
Article
Dermatology
Abby S. Van Voorhees, Marc A. Mason, Leslie R. Harrold, Ning Guo, Adriana Guana, Haijun Tian, Vivian Herrera, Bruce E. Strober
Summary: This study analyzed characteristics and outcomes of US patients with moderate-to-severe psoriasis who had insufficient responses to ustekinumab, finding a significant association between increasing age and decreased likelihood of achieving a response to the treatment.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2021)
Article
Dermatology
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Rosa Giuseppa Angileri, Federico Bardazzi, Nicoletta Bernardini, Martina Burlando, Carlo G. Carrera, Andrea Chiricozzi, Paolo Dapavo, Valentina Dini, Gabriella Fabbrocini, Francesca Maria Gaiani, Marco Galluzzo, Claudia Giofre, Claudio Guarneri, Francesco Loconsole, Giovanna Malara, Lorenzo Marcelli, Matteo Megna, Stefano Piaserico, Marina Talamonti, Antonio Costanzo, Alessandra Narcisi
Summary: This retrospective study on 233 patients with moderate-to-severe plaque psoriasis who had an inadequate response to ustekinumab showed that guselkumab was more effective in achieving PASI 75/90/100 compared to ustekinumab.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Dermatology
Seungkeol Yang, Bo Ri Kim, Minsu Kim, Sang Woong Youn
Summary: Ustekinumab showed efficacy in treating toenail psoriasis, with significant improvements in NAPSI scores of the first and second toes. Certain characteristics hindered NAPSI scoring during the study.
ANNALS OF DERMATOLOGY
(2021)
